Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NLS Pharmaceutics Ltd. Regulatory Filings 2021

Apr 5, 2021

35193_ffr_2021-04-05_2f04178f-b95d-4460-84a4-6114c323ad46.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

6-K 1 ea138964-6k_nlspharmaceutics.htm REPORT OF FOREIGN PRIVATE ISSUER

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of April 2021

Commission file number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

Alter Postplatz 2

CH-6370 Stans, Switzerland

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

CONTENTS

Appointment of New Chief Operating Officer

On April 5, 2021, the Registrant announced that Silvia Panigone, Ph.D. has been appointed as the Chief Operating Officer of the Registrant.

A copy of the Registrant’s press release containing this announcement is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.

Field: Page; Sequence: 2; Options: NewSection; Value: 1

Field: Sequence; Type: Arabic; Name: PageNo 1 Field: /Sequence

Field: /Page

EXHIBIT INDEX

Exhibit No.
99.1 Press release titled: “NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer.”

Field: Page; Sequence: 3; Value: 1

Field: Sequence; Type: Arabic; Name: PageNo 2 Field: /Sequence

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

/s/ Alexander Zwyer
Name: Alexander Zwyer
Title: Chief Executive Officer

3

Field: Rule-Page

Field: /Rule-Page